Core Insights - Scinai Bioservices, a CDMO unit launched by Scinai in 2024, operates from a facility in Jerusalem, Israel, featuring 1,850 square meters of clean rooms and laboratories compliant with cGMP standards [2][3] - The CDMO unit has engaged in drug development projects for various biotech companies, including upstream and downstream process development, scale-up, and drug manufacturing for clinical trials [3] - Scinai's U.S. subsidiary aims to support early-stage biotech companies by providing essential CDMO services that are currently in short supply, allowing startups to utilize government grant funding [4] Company Overview - Scinai Immunotherapeutics Ltd. is a biopharmaceutical company with two main business units: one focused on developing biological therapeutic products for inflammation and immunology, and the other providing CDMO services to early-stage biotech companies [5] - The company is actively seeking potential pharma partners interested in co-developing or in-licensing its innovative NanoAbs targeting diseases with significant unmet medical needs [7] Business Development - Scinai has partnered with Ayana Pharma to offer liposomal encapsulated drug development services, enhancing its capabilities in the CDMO sector [3] - The company is positioned to attract institutional and private investors by showcasing its value proposition in the biopharmaceutical market [7]

Core Insights - Humanetics Corporation is developing BIO 300, a novel radioprotective agent aimed at preventing acute radiation syndrome, with support from the Department of Defense [1][3] - Lifecore Biomedical has been selected to provide contract development and manufacturing services for BIO 300, including technology transfer and analytical method activities [1][2] - The collaboration highlights the innovation within Minnesota's life sciences sector and aims to provide critical protection against radiation exposure for military personnel and civilians [2] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products, with over 40 years of experience [4] - Humanetics Corporation focuses on the discovery and development of proprietary drugs for urgent medical needs, particularly in radiation countermeasures and oncology [5] Financial Support - The development of BIO 300 is supported by a grant of $5,132,520 from the Department of Defense through the Peer Reviewed Medical Research Program [3]

Core Insights - Avid Bioservices, Inc. has launched a new corporate website aimed at enhancing visitor experience for current and prospective customers [1][2][3] Company Overview - Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on biologics, providing a comprehensive range of services including CGMP clinical and commercial manufacturing [4] - The company has over 30 years of experience in producing biologics and offers services such as process development, bulk packaging, and regulatory submissions support [4] Website Features - The new website features an improved user experience with user-friendly navigation, enhanced accessibility, video interaction, and educational resources [2][3] - The tagline "Discover the Avid effect.™" is used to highlight the company's differentiation and position as a trusted biologics CDMO [2] Leadership Perspective - The CEO of Avid emphasized the importance of aligning the online presence with the company's commitment to exceptional quality service and customer satisfaction [3]

Core Points - Avid Bioservices, Inc. announced a Fundamental Change and a Make-Whole Fundamental Change occurred on February 5, 2025, due to the closing of a merger transaction [1][2][5] - Holders of the 7.00% Convertible Senior Notes due 2029 have the right to require the company to repurchase their notes at 100% of the principal amount plus accrued interest on March 12, 2025 [2][4] - The company will increase the Conversion Rate for notes surrendered for conversion during the Make-Whole Fundamental Change Conversion Period, which ends on March 10, 2025 [5][10] Company Overview - Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on biologics, providing a range of services including process development and CGMP manufacturing for biotechnology and pharmaceutical companies [13]

Acquisition Overview - GHO Capital Partners and Ampersand Capital Partners have successfully closed the acquisition of Avid Bioservices, a dedicated biologics Contract Development and Manufacturing Organisation (CDMO), in an all-cash transaction valued at approximately $1.1 billion [1][4][7] - Avid's stockholders will receive $12.50 per share in cash, and the company's common stock will be delisted from Nasdaq [4][7] Company Growth and Capabilities - Avid has experienced significant growth, offering full lifecycle capabilities from concept to commercial supply, with substantial investments in state-of-the-art facilities and expertise in bioprocess optimization, analytical testing, and regulatory compliance [2][9] - The company provides a comprehensive range of services including CGMP clinical and commercial drug substance manufacturing, bulk packaging, and regulatory submissions support, leveraging over 30 years of experience in producing biologics [9] Strategic Focus of GHO and Ampersand - GHO has considerable expertise in the CDMO sector, focusing on expanding technological capabilities, driving acquisitions, and supporting transatlantic expansion across the CDMO value chain [3][10] - Ampersand Capital Partners, with $3 billion in assets under management, is dedicated to growth-oriented investments in the healthcare sector, leveraging a blend of private equity and operating experience to build value [10] Leadership Insights - GHO's Managing Partners expressed excitement about the acquisition, highlighting Avid's strong foundation for future growth and the potential to unlock the business's full potential [4] - Avid's President and CEO noted that the new ownership will provide access to resources that will accelerate growth and enhance capabilities [4]

Core Insights - GHO Capital Partners and Ampersand Capital Partners have successfully completed the acquisition of Avid Bioservices for approximately $1.1 billion, marking GHO's first public to private deal [1][4][7] - Avid Bioservices specializes in biologics Contract Development and Manufacturing Organization (CDMO) services, providing full lifecycle capabilities from concept to commercial supply [2][9] - The acquisition aims to leverage GHO and Ampersand's expertise in the CDMO sector to support Avid's growth, enhance service offerings, and expand geographic reach [3][4][10] Company Overview - Avid Bioservices has made significant investments in its state-of-the-art facilities and expertise in bioprocess optimization, analytical testing, and regulatory compliance, positioning itself as a leader in the biopharmaceutical development and manufacturing sector [2][9] - The company offers a comprehensive range of services, including CGMP clinical and commercial manufacturing, bulk packaging, and regulatory submissions support, with over 30 years of experience in producing biologics [9] Investment Strategy - GHO Capital's strategy focuses on expanding technological capabilities and supporting transatlantic expansion across the CDMO value chain, from early-stage development to commercial manufacturing [3] - Ampersand Capital Partners, with $3 billion in assets under management, is dedicated to growth-oriented investments in the healthcare sector, leveraging its private equity and operating experience to build value [10]

Group 1 - Avid Bioservices, Inc. has received stockholder approval for its transaction with GHO Capital Partners LLP and Ampersand Capital Partners [1][2] - The company anticipates closing the transaction in the coming days, as all closing conditions have been met and regulatory approvals obtained [2] - Avid Bioservices is a dedicated biologics contract development and manufacturing organization, providing a comprehensive range of services for biotechnology and biopharmaceutical industries [3] Group 2 - The company has over 30 years of experience in producing biologics, offering services that include CGMP clinical and commercial drug substance manufacturing, bulk packaging, and regulatory submissions support [3] - Avid's services range from standalone process development projects to full development and manufacturing programs through commercialization [3]

Core Points - Avid Bioservices is in the process of a transaction with GHO Capital Partners and Ampersand Capital Partners, which is expected to deliver significant, immediate, and certain cash value to stockholders [1][6] - The transaction has received recommendations from leading independent proxy advisory firms, ISS and Glass Lewis, to vote in favor of the deal [3][6] - Avid's Board of Directors conducted a robust process to maximize stockholder value, including engaging multiple strategic and financial parties [7][6] Company Overview - Avid Bioservices is a dedicated biologics contract development and manufacturing organization (CDMO) that provides high-quality development and manufacturing services to biotechnology and pharmaceutical companies [1][11] - The company has over 30 years of experience in producing biologics and offers a comprehensive range of services, including CGMP clinical and commercial manufacturing [11] Transaction Details - The Special Meeting for stockholders to vote on the transaction is scheduled for January 30, 2025, with eligible stockholders as of December 11, 2024 [2] - The proposed transaction offers a compelling valuation with a significant premium of 63.8% over the company's closing price of $7.63 on June 4, 2024, and a premium of 24.9% compared to the trading multiples of comparable publicly traded companies [4][6] - The transaction is seen as a de-risking move for Avid's future as a standalone company amid industry-wide uncertainties [5][6] Voting and Advisory - The Avid Board of Directors unanimously recommends that stockholders vote "FOR" the proposed transaction [9] - Stockholders are encouraged to vote through various methods, including online, by phone, or by returning the proxy card [8]

Core Viewpoint - Avid Bioservices, Inc. has received recommendations from leading independent proxy advisory firms ISS and Glass Lewis to vote "FOR" the proposed transaction with GHO Capital Partners LLP and Ampersand Capital Partners, indicating a favorable outlook for stockholders [1][2]. Company Overview - Avid Bioservices is a dedicated biologics contract development and manufacturing organization (CDMO) that provides high-quality development and manufacturing services to biotechnology and pharmaceutical companies [1][5]. - The company has over 30 years of experience in producing biologics and offers a comprehensive range of services including CGMP clinical and commercial drug substance manufacturing, bulk packaging, and regulatory submissions support [5]. Transaction Details - The transaction with GHO and Ampersand is viewed as providing a premium value for Avid stockholders, with ISS noting that the sales process was thorough and the cash consideration offers liquidity and certainty of value [2]. - The Avid Board of Directors has unanimously recommended that stockholders vote "FOR" the proposed transaction [3]. Advisory Information - Moelis & Company LLC is serving as the exclusive financial advisor to Avid, while Cooley LLP is providing legal counsel [4].

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm ...